Aim To evaluate final height in a cohort of Dutch childhood cancer survivors (CCS) and assess possible determinants of final height, including height at diagnosis.
Introduction
Over the last five decades improvements in the treatment of childhood cancer have resulted in dramatically increased survival rates. 1 However, oncologic treatment may induce different late effects. The quality of life of childhood cancer survivors (CCS) may be impaired by these late effects. 2, 3 Research on these late effects can improve quality of survivorship, for instance by earlier detection of health problems in this patient group, and adequate and earlier treatment. Future patients may benefit from this research as most toxic elements of therapy are identified and future treatment schemes may be adapted as long as survival rates are not influenced.
One of the possible late effects of childhood cancer therapies is reduced final height. Growth impairment can negatively impact quality of life, especially in individuals with a low a priori target height. Impaired growth may hamper the social development of these children, who often already feel different from their peers due to other late effects. The association between impaired growth resulting in a decreased final height and childhood cancer therapy was previously investigated in 1997 with data of the first consecutive 285 CCS seen at our late effects outpatient clinic. 4 Currently, 15 years later, all CCS of our late effects outpatient clinic have been identified and the cohort includes over 1500 survivors.
It is assumed that cancer treatment in childhood can influence final height through three major pathways. Firstly, skeletal growth may directly be influenced by cranial, spinal or abdominal radiation therapy. 5, 6 A second cause is the disturbance of hormone secretion by the hypothalamus and the pituitary gland, caused by radiation damage or a brain tumour. 7 These disturbances may result in hypothyroidism, growth hormone deficiency and/or precocious puberty. 4, 8, 9 Finally, it has been hypothesized that short stature can be a result of treatment with (chronic) steroids, treatment with chemotherapy, graft versus hostdisease or underweight. 10, 11 Besides these aforementioned factors, final height is determined by genetic factors. However, in most studies addressing final height after childhood cancer treatment, height at diagnosis or familial constitution are not taken into consideration. One relatively small cohort study by Talvensaari et al. found that children with tall stature at diagnosis were at increased risk for reduced final height compared to children with short stature. 12 In contrast to this finding, van Waas et al. recently assessed 84 survivors of nonHodgkin lymphoma (NHL) and reported that lower adult height was most likely due to lower height at diagnosis. 13 They did not find any treatment-related risk factors.
The goal of this study was to assess final height in a large cohort of CCS and to assess the influence of (treatment-related)
covariates, including height at diagnosis, for survivors' final height.
Methods

Study population and data collection
In 1996, the Late Effects Outpatient Clinic for CCS was established in the Emma Children's Hospital/Academic Medical Centre (EKZ/AMC). All five-year CCS were invited for regular screening according to standardized follow-up protocols adapted to the patient's previous treatment modalities. The patient data are recorded in a hospital database, including information on patient demography, diagnosis, therapy and outcomes. 14 To be eligible for inclusion in this study, survivors had to match the following inclusion criteria: 1) diagnosed and treated for childhood cancer in EKZ/AMC between 1966 and 2003; 2) survived ≥5 years after diagnosis; 3) aged ≥18 years Table 3 ). 15 Survivors could have been irradiated on more than one region.
Outcome measurements
Final height was defined as the first height measurement in our outpatient clinic at a minimal age of 18 years. Final height was available from the electronic medical record, height at diagnosis was recovered from initial patient records.
Height standard deviation scores (SDS) were calculated with two reference standards based on the normal population from two different decades, to correct for secular growth changes in the Netherlands. [16] [17] [18] All SDS were calculated to correct for age and sex. Short stature was defined as a final height below -2SD.
Growth hormone deficiency was defined as having received growth hormone treatment after completion of cancer treatment.
Statistics
Descriptive statistics are presented as mean (SD) for normally distributed variables or median (minimum-maximum) for variables without a normal distribution. To test whether the SDS of our population differed from the normal population onesample T-tests were used. The difference between height SDS at diagnosis and height SDS at follow-up was tested with paired T-tests.
To model the effect of potential risk factors on height SDS at follow-up, we built a multivariable linear regression model that included age at diagnosis and height were excluded due to a missing adult height measurement and another 504
were excluded due to a missing height measurement at diagnosis. From 573 survivors data of height at diagnosis of the malignancy and at follow-up could be retrieved and these were hence included in this study. Figure 1 shows the cohort composition. Abdominal only 37 (6.5%) 48 (9.5%) 6 (4.5%)
Lower extremities only 0 (0.0%) 2 (0.4%) 0 (0.0%) (Table 3) .
Final height in survivors of childhood cancer compared to height standard deviation scores at diagnosis | 175 Survivors could be irradiated on more than 1 field. * The EQD 2 was calculated using the formula EQD 2 = D * (d+α/ß)/(2+α/ß). The total dose D is the number of fractions multiplied by the fraction size d. The α/ß ratio originates from the linear quadratic model; its value depends on the tissue under consideration. We used an α/ß ratio of 3 Gray (Gy) for late responding tissues. The EQD 2 for the cranial region only included boost doses when the pituitary gland was in the field. The EQD 2 for the spinal and abdominal region includes boost doses under the condition that the spine was in the booster field. The EQD 2 for the cranial region only includes boost doses when the pituitary gland was in the field. † Four patients received orbital brachytherapy. Calculation of the EQD 2 -dose for orbital brachytherapy was performed using the formula EQD 2 = D*(d*g+α/ß)/(2+α/ß), where D is the total dose (dose rate*exposure time) and d equals D in case of continuous single exposures. The repair factor g has to be calculated: g = 2*[μ*t -1 + exp(-μ*t)]/( μ*t) 2 where t is the exposure time and μ includes the repair half time T½: μ = log e 2/T½. For late responding tissue the T½ is estimated at 3.5 hours. [15, 31] Abbreviations: EQD 2 : equivalent dose in 2-Gray fractions. Gy: Gray; RT: radiotherapy; TBI: total body irradiation.
Height SDS at diagnosis and final height SDS after treatment for childhood cancer
Overall, survivors had a significant reduced final height at follow-up (mean loss of height SDS: -0.29; P<0.001). Fifty one survivors (8.9 %) had short stature at final height, defined as final height ≤-2 SDS. Table 4 shows height SDS at diagnosis and at follow-up in relation to the different tumour types and treatment groups.
Overall, survivors were not significantly smaller than the general population at *: P value for the difference with the normal Dutch population with a mean SDS of 0.0 by definition (one-sample T-test). †: P value for the difference between the SDS at diagnosis and the SDS at follow-up (paired T-test). ‡: survivors can be included in more than one treatment group. Abbreviations: SDS: standard deviation score; ALL: acute lymphoblastic leukaemia; AML: acute myeloid leukaemia; CNS: central nervous system; TBI: total body irradiation.
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Multivariable risk factor analysis
In order to assess the influence of different determinants on final height SDS, multivariable linear and logistic regression analyses were performed. Linear regression analysis showed that age at diagnosis, height SDS at diagnosis, treatment with cranial irradiation, spinal irradiation and/or TBI, use of anthracyclines and use of other chemotherapeutics all significantly contributed to final height SDS (Table 5) . Cranial radiotherapy and TBI had the highest impact 
Discussion
In this large cohort of adult CCS with heights measured at time of diagnosis and at final height (n=573), nearly 10 per cent had significant and clinical relevant reduced final height (height SDS ≤-2). Furthermore, on average, all children had significant height loss compared to their height at diagnosis. We demonstrated that height at diagnosis was a major determinant for final height; the taller the child at diagnosis, the taller the survivor after treatment for childhood cancer.
Additionally, we confirmed that cranial and spinal irradiation, TBI and younger age at diagnosis contribute negatively to final height. We also established significant dose-response relationships between the cumulative EQD 2 and the final height SDS and short stature.
The normal height SDS at initial diagnosis of malignancy was an important finding:
children presenting with malignant disease have no loss of height, regardless of the type of tumour. This is in contrast to the findings of van Waas et al., who noted that the height at diagnosis of NHL patients was already significantly lower in comparison to healthy controls and that height SDS remained lower throughout follow-up. 13 Apparently, the metabolic and endocrine state of the child diagnosed with cancer is comparable to the general population in respect to linear growth. This clearly changed during treatment, resulting in a reduced final height in almost 10% of young adults with a history of childhood cancer.
We found that children who had a shorter stature at diagnosis were at increased risk to have a reduced final height at follow-up. This is in conflict with the results of Talvensaari, who described in a small cohort (n=51) that children with the tallest height at diagnosis were most at risk to have an impaired growth after treatment for childhood cancer. 12 Our findings may be explained by genetic and with parental height data to calculate target height SDS and with patient race, but these were not recorded in our database. This is a limitation of our study.
Using height SDS at diagnosis, however, gives in our opinion a reliable estimate of the genetic predisposition for target height.
Overall, survivors had a reduced final height (mean loss of height SDS: -0.27; We could not assess onset of puberty or the exact time of start of GH treatment for the survivors in our study. The relation between onset of puberty and final height was however previously studied by Noorda et al. who found significantly earlier menarche in 124 girls after cranial irradiation. 4 Groot-Loonen et al. also
described an earlier onset of puberty and menarche and shorter duration of the pubertal growth spurt in children treated for acute lymphoblastic leukaemia (ALL), resulting in a shorter than expected final height. 24 Final height in survivors of childhood cancer compared to height standard deviation scores at diagnosis | 181
There is still much debate on the effects of chemotherapy on final height.
11
It has been suggested that growth is more severely affected in children who have had both chemotherapy and radiation treatment. 25 Also Ogilvy-Stuart and Shalet showed a profound effect of chemotherapy on final height. 26, 27 Temporary height loss was described in children with ALL who did not receive radiotherapy, but these patients attained normal adult heights thanks to sufficient catch-up growth. 28 In our linear regression analyses, treatment with anthracyclines or with other chemotherapeutic agents lowered final height significantly (Table 5 ).
We could not confirm these effect in the logistic regression analyses, probably because these agents do not result in GHD and do not result in final height ≤-2
SDS .
It is unclear what the pathophysiological mechanism is for anthracyclines on height reduction, but they have previously been related to the development of underweight. 29, 30 It may be hypothesized that CCS with underweight lose height due to malnutrition and low IGF-1 levels. Additional studies are warranted into the effects of chemotherapy and linear growth.
Strengths of our study include the size of our cohort, including all types of tumours, the completeness of both treatment and follow-up data and the inclusion of pre-treatment height measurements as an important determinant in the regression models. The inclusion of pre-treatment data is not often done, but is essential for a correct interpretation of tumour-and treatment-related late effects in CCS. Only when follow-up patient characteristics are compared to the characteristics of the patient at time of diagnosis, causality between the tumour and its treatment and a specific late effect can be studied and pre-or coexisting conditions can be ruled out.
Weaknesses of our study are the lack of data concerning onset of puberty, parental heights, race and the high percentage of missing data regarding height at diagnosis. This may have introduced an information bias, as normal heights may not have been recorded as much as abnormal values. However, the groups with and without a measurement at diagnosis proved to be comparable on almost all parameters. Due to the retrospective nature of data collection, we cannot exclude that some height measurements at diagnosis were taken while the patient was stretched due to serious illness. We also were not able to take the Tanner stages of survivors into consideration, which may have led to an underestimation of the final height SDS's, as a small percentage of the younger survivors may not have reached final height at age 18 yet.
Future prospective studies should focus on early diagnostics of GH deficiency and the exact effect of GH treatment on growth velocities in the different subgroups of CCS. In the current study, we assumed that the treating physician adequately evaluated the presence of GHD and timely started treatment with GH, but we did not have the exact information on the doses and duration of GH treatment. Additionally, adding delta arm length (D-SDS arm) to total body height and sitting/height ratio may be interesting in the future to validate catchup growth after cranial versus spinal radiation therapy.
In conclusion, the majority of children treated for cancer have a significantly reduced final height SDS compared to height SDS at diagnosis and almost
10% have a clinically significant lower final height (≤-2 SDS). Final height SDS
is largely determined by height SDS at diagnosis, but increased risk to develop short stature is present after treatment with spinal and/or cranial irradiation and TBI. Furthermore, a dose-response relationship exists between the cumulative EQD 2 and the final height SDS. The exact effect of anthracyclines on height in CCS must be further evaluated. All children, especially those with a small target height SDS, treated with one of these three modalities should be monitored periodically for growth velocity, body weight, the development of GHD and the onset of puberty, for timely intervention to improve final height.
